ARTICLE | Clinical News

Livalo pitavastatin regulatory update

August 23, 2010 7:00 AM UTC

The U.K.'s MHRA approved an MAA from Kowa for pitavastatin as adjunct to diet to treat primary hypercholesterolemia and combined dyslipidemia. The application was submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Kowa said pitavastatin has also been approved in the Netherlands. Kowa and Nissan Chemical Industries Ltd. (Tokyo, Japan) co-developed the HMG-CoA reductase inhibitor. ...